) reported positive top-line results from the first two steps of
the phase II CLEAR (C5aR inhibitor on Leukocytes Exploratory
ANCA-associated Renal Vasculitis) study on its candidate, CCX168.
A C5aR (chemoattractant receptor) inhibitor, CCX168 is being
developed for the treatment of anti-neutrophil cytoplasmic
antibody (ANCA)-associated renal vasculitis (AARV).
ACTELION LTD (ALIOF): Get Free Report
AMAG PHARMA INC (AMAG): Free Stock Analysis
CHEMOCENTRYX (CCXI): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
To read this article on Zacks.com click here.
Results from the study revealed that CCX168 was generally safe
and well tolerated. The candidate was also successful in the
reduction and elimination of high-dose corticosteroids, a part of
standard of care for patients suffering from AARV. Moreover, the
efficacy or safety profile of the candidate was not hampered
during the reduction and elimination of high-dose
ChemoCentryx also reported improvements in a number of renal
health parameters like renal remission, albuminuria and
Birmingham vasculitis activity score (BVAS), in patients under
CCX168 compared to those under standard of care treatment. No
unexpected serious adverse events were observed in patients under
CCX168 during the study.
We note that in Aug 2006, ChemoCentryx had entered into a
worldwide strategic agreement with
) for CCX168. Two other candidates, vercirnon (Crohn's disease)
and CCX354 (rheumatoid arthritis), were also part of the
agreement. ChemoCentryx stated in its press release that Glaxo
has rejected its option to license CCX168.
As a result, ChemoCentryx regained full development and
commercial rights of CCX168. In Sep 2013, Glaxo returned all
rights to vercirnon and ChemoCentryx became solely responsible
for developing vercirnon for all indications including
inflammatory bowel disease and Crohn's disease.
Glaxo took this decision after vercirnon failed to meet both the
primary and the key secondary endpoint in the SHIELD-1 phase III
study (first of four phase III studies) in Aug 2013. Glaxo was
evaluating the use of vercirnon in adults suffering from
moderately-to-severely active Crohn's disease.
ChemoCentryx presently carries a Zacks Rank #3 (Hold). Some
better ranked stocks include
AMAG Pharmaceuticals, Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).